Precision BioSciences' First-in-Class Gene Editing Therapy PBGENE-HBV Shows Dose-Dependent Antiviral Response And Evidence Of Viral DNA Editing In Phase 1 ELIMINATE-B Study, Offering Potential Path Toward Chronic Hepatitis B Cure; To Host Conference Call Tomorrow, November 11th At 8:00 am ET

Author: Benzinga Newsdesk | November 10, 2025 05:25pm

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at 5:45pm EST on Monday, November 10, 2025

PBGENE-HBV was well-tolerated across pre-planned repeat administrations at doses of 0.2mg/kg, 0.4 mg/kg, and 0.8mg/kg with no dose-limiting toxicities

Data to date from the Phase 1 ELIMINATE-B study demonstrates dose-dependent antiviral response, with activity observed in all nine patients across 22 doses in first three study cohorts

All three patients in highest dose cohort (0.8 mg/kg) showed steep declines of HBsAg at day 14 with evidence of cumulative declines in HBsAg after second administration of PBGENE-HBV in sentinel subject

Data suggests a potential path towards nucleos(t)ide withdrawal and testing for cure if confirmed with additional dose administrations and longer follow up

Paired biopsy data to date provides first evidence of viral DNA gene editing and directly correlates with observed HBsAg reductions

Company to host conference call tomorrow, November 11th at 8:00AM ET

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA.

The presentation, to be delivered by Dr. Man-Fung Yuen, Chair Professor of Gastroenterology and Hepatology at The University of Hong Kong, features new data from nine patients across 22 doses in the first three cohorts of the ELIMINATE-B trial. A copy of the presentation will be available on the Company's website.

Posted In: DTIL